Not sure what is going on in Missling's mind:
Points to ponder about -
* He evidently has access to the latest data from the extended trial - that should help him decide his course of action and priorities.
* He has enough money to run the 2 relatively short duration trials - each being 12 week duration with some funding for the Rett trial from the Rett org.
* He has one ex-FDA guy in the organization who is obviously an expert in dealing with FDA; the nuances, the roadblocks and bumps along the road.
* He is buying shares in bits and pieces - as if to send a signal that something positive is bound to happen ( according to longs) or otherwise (just misleading people to buy, according to nay sayers)
Then there is the recent 21 Century Cures Act and how the FDA has reprogrammed itself to enhance and speed up the process of drug approval
Finally, going by what he has said before, the company plans to start 3 trials during the 2H of this year. We only have 100 days left and I am sure starting 2 out of 3 in the next 100 days would not damage his credibility, as long as he comes out at the right time and gives an update with a solid plan or reason for delaying the 3rd trial (I still think, he can pull it off - technically at least by announcing in mid December that they are open for enrollment for the 3rd trial - assuming that it is AD trial).
This brings an interesting question - does he have enough data from the extended trial for him to finally decide that he would go for the Rett trial, followed by AD trial and push the starting of PD trial to the 3rd slot? Is that the reason for trying to sell some shares to LPC - to ensure full funding for the AD trial? These are just my thoughts - trying to figure out the reason why Missling is quiet, the delay, total lack of communication/rumor. Of course there is a possibility that the extended trial data is not as good as expected - wont be a big surprise.
